Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder

Documenti analoghi

• Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
  di: Chia‐Chih Kuo, et al.
  Pubblicazione: (2025)
• Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
  di: Luis Antonio Díaz, et al.
  Pubblicazione: (2025)
• Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
  di: Xing Bai, et al.
  Pubblicazione: (2025)
• Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
  di: Luis Antonio Díaz, et al.
  Pubblicazione: (2025)
• Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
  di: Joëlle St‐Pierre, et al.
  Pubblicazione: (2026)